Literature DB >> 10594896

Phospholipaise A2 and arachidonic acid-mediated mechanism of neuroexocytosis: a possible target of botidinum neurotoxin A other then SNAP-25.

P Ray1, H Ishida, C B Millard, J P Petrali, R Ray.   

Abstract

The vesicular neuroexocytosis process consists of two important steps: fusion of transmitter-loaded vesicles at release sites on the presynaptic nerve terminal membrane; followed by the release of transmitter molecules into the synaptic cleft. We previously reported that in nerve growth factor (NGF)-differentiated PC12 cells, arachidonic acid (AA) release is associated with acetylcholine (ACh) release, botulinum neurotoxin A (BoNT/A) inhibits both processes and AA itself or a phospholipase A(2) (PLA(2)) activator can cause ACh release in BoNT/A-poisoned cells in which SNAP-25 has supposedly been hydrolyzed. In the present study, we examined the roles of two endogenous intraterminal components in neuroexocytosis: the membrane fusogenic agent AA; and the vesicle fusion protein SNAP-25. A PLA(2) activator, mastoparan, was used to induce the release of AA and ACh from NGF-differentiated PC12 cells. Release depended upon the mastoparan concentration, as well as Ca(2+) influx via the neuronal-type voltage-sensitive Ca(2+) channels. Release of ACh followed a rise in intracellular free Ca(2+) concentration; the increased Ca(2+) activated PLA(2) and, thereby, increased the AA level. Scanning and transmission electron microscopy confirmed that mastoparan-induced ACh and AA release were not due to simple diffusion through damaged plasma membranes. Treatment of PC12 cells with appropriate antisense oligonucleotides blocked SNAP-25 expression, as judged by Western blot protein analysis with a specific monoclonal antibody. Despite apparent elimination of SNAP-25, treatment of differentiated PC12 cells with mastoparan and high (80 mM) K(+) induced ACh exocytosis. The results support the conclusion that PLA(2) and AA have important roles in neuroexocytosis that are independent of SNAP-25. Both PLA(2) and AA have been shown to be involved in actin cytoskeletal organization related to vesicle fusion and exocytosis. This mechanism may be an alternative target of BoNT/A other than SNAP-25.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10594896     DOI: 10.1002/(sici)1099-1263(199912)19:1+<s27::aid-jat610>3.0.co;2-a

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  6 in total

1.  Differential effects of polyunsaturated fatty acids on membrane capacitance and exocytosis in rat pheochromocytoma-12 cells.

Authors:  Wee-Liat Ong; Bin Jiang; Ning Tang; Su-Fung Ling; Jin-Fei Yeo; Shunhui Wei; Akhlaq A Farooqui; Wei-Yi Ong
Journal:  Neurochem Res       Date:  2006-01       Impact factor: 3.996

2.  Decreased phospholipase A2 activity in cerebrospinal fluid of patients with dementia.

Authors:  Stefan Smesny; Susan Stein; Ingo Willhardt; Jürgen Lasch; Heinrich Sauer
Journal:  J Neural Transm (Vienna)       Date:  2008-06-27       Impact factor: 3.575

3.  The mechanism of botulinum A on Raynaud syndrome.

Authors:  Yanwen Zhou; Ying Liu; Yunhua Hao; Ya Feng; Lizhen Pan; Wuchao Liu; Bing Li; Libin Xiao; Lingjing Jin; Zhiyu Nie
Journal:  Drug Des Devel Ther       Date:  2018-06-26       Impact factor: 4.162

Review 4.  Therapeutic use of botulinum toxin in pain treatment.

Authors:  Raj Kumar
Journal:  Neuronal Signal       Date:  2018-08-31

5.  Combined targeted Omic and Functional Assays Identify Phospholipases A₂ that Regulate Docking/Priming in Calcium-Triggered Exocytosis.

Authors:  Deepti Dabral; Jens R Coorssen
Journal:  Cells       Date:  2019-04-02       Impact factor: 6.600

6.  Cytosolic PLA2 is required for CTL-mediated immunopathology of celiac disease via NKG2D and IL-15.

Authors:  Fangming Tang; Zhangguo Chen; Cezary Ciszewski; Mala Setty; Jason Solus; Maria Tretiakova; Ellen Ebert; Jin Han; Anning Lin; Stefano Guandalini; Veronika Groh; Thomas Spies; Peter Green; Bana Jabri
Journal:  J Exp Med       Date:  2009-02-23       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.